Pharmesis International Ltd.

BFK

SG1BH6000003

Pharmaceuticals

Delayed Singapore S.E. Other stock markets 08:48:47 21/05/2024 am IST			5-day change	1st Jan Change
0.08 ^SGD	-18.37%		-23.81%	-18.37%

30/04	Pharmesis International Ltd. Approves the Appointment of Seow Yong Teng as Lead Independent Director	CI
30/04	Pharmesis International Ltd. Announces Re-Designation of Chew Heng Ching to Non-Independent Non-Executive Chairman	CI

Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020

August 14, 2020 at 02:49 pm IST

Pharmesis International Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 19.670 million compared to CNY 18.444 million a year ago. Operating loss was CNY 3.427 million compared to CNY 5.309 million a year ago. Net loss was CNY 3.670 million compared to CNY 4.924 million a year ago.

Latest news about Pharmesis International Ltd.

Pharmesis International Ltd. Approves the Appointment of Seow Yong Teng as Lead Independent Director	30/04	CI
Pharmesis International Ltd. Announces Re-Designation of Chew Heng Ching to Non-Independent Non-Executive Chairman	30/04	CI
Pharmesis International Ltd. Announces Retirement of Lin Yimin as Member of Audit Committee	29/04	CI
Pharmesis’ Attributable Loss for 2023 Widens	15/04	MT
Pharmesis International Ltd. Announces the Retirement of Ms. Lin Yimin as a Director	15/04	CI
Pharmesis Launches New Product Line	26/03	MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months and Full Year Ended 31 December 2023	28/02	CI
Pharmesis International Ltd. Announces Changes to the Composition of the Board and Board Committees	29/23/29	CI
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/23/14	CI
Pharmesis International Flags Losses for H1	09/23/09	MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023	08/23/08	CI
Pharmesis International Ltd. Announces Management Resignations	31/23/31	CI
Pharmesis International Ltd. Appoints Lin Yimin as Non-Independent Non-Executive Director and A Member of Audit Committee	31/23/31	CI
Pharmesis International Ltd. Announces Temporary Work Stoppages at its Manufacturing Facilities Located in Gulin County, Luzhou City, Sichuan Province	27/23/27	CI
Pharmesis International Issues 4.6 Million Shares to Two Subscribers	06/23/06	MT
Pharmesis International Gets Regulatory Nod to List 4.6 Million Shares	29/23/29	MT
Pharmesis International to Issue 4.6 Million Shares to Two Subscribers	21/23/21	MT
Pharmesis International Expects Loss in H2, FY22	28/23/28	MT
Pharmesis International Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Pharmesis International's Attributable Loss Widens in H1	15/22/15	MT
Pharmesis International Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	12/22/12	CI
Pharmesis International to Post Losses in H1 Amid Lower Sales	08/22/08	MT
Pharmesis International Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2022	05/22/05	CI
Pharmesis International Ltd. Appoints Cheok Hui Yee as Company Secretary	30/22/30	CI

Chart Pharmesis International Ltd.

Duration

Period

More charts

Company Profile

Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMESIS INTERNATIONAL LTD.	-18.37%	16.36L
ELI LILLY AND COMPANY	+37.74%	72TCr
NOVO NORDISK A/S	+32.22%	59TCr
JOHNSON & JOHNSON	-2.07%	37TCr
MERCK & CO., INC.	+20.25%	33TCr
ABBVIE INC.	+2.99%	28TCr
ASTRAZENECA PLC	+16.60%	24TCr
NOVARTIS AG	+9.77%	21TCr
ROCHE HOLDING AG	-5.15%	21TCr
AMGEN INC.	+7.43%	17TCr